About Invex Therapeutics
Invex Therapeutics Limited (ASX:IXC) is a biopharmaceutical company focused on repurposing the approved drug Exenatide, trademarked as Presendin™, for the treatment of neurological conditions involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke, and traumatic brain injury. The company is advancing clinical development of Presendin™ particularly for IIH. Invex aims to provide effective, evidence-based therapies for patients with these critical neurological disorders.